Yoshimi Matsuda

577 total citations
17 papers, 203 citations indexed

About

Yoshimi Matsuda is a scholar working on Hematology, Nephrology and Genetics. According to data from OpenAlex, Yoshimi Matsuda has authored 17 papers receiving a total of 203 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 8 papers in Nephrology and 5 papers in Genetics. Recurrent topics in Yoshimi Matsuda's work include Erythropoietin and Anemia Treatment (11 papers), Dialysis and Renal Disease Management (7 papers) and Blood transfusion and management (5 papers). Yoshimi Matsuda is often cited by papers focused on Erythropoietin and Anemia Treatment (11 papers), Dialysis and Renal Disease Management (7 papers) and Blood transfusion and management (5 papers). Yoshimi Matsuda collaborates with scholars based in Japan, Germany and France. Yoshimi Matsuda's co-authors include Hiroyasu Yamamoto, Tadao Akizawa, Kiyoshi Nobori, Yasuhiro Hayashi, Takanori Hayasaki, Takashi Yamada, Kazuma Iekushi, Takashi Shigematsu, Kazuaki Shimamoto and Keiichi Fukuda and has published in prestigious journals such as Journal of the American Society of Nephrology, Investigative Ophthalmology & Visual Science and Nephrology Dialysis Transplantation.

In The Last Decade

Yoshimi Matsuda

17 papers receiving 201 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yoshimi Matsuda Japan 9 132 68 67 57 36 17 203
Zeeshan Khawaja United Kingdom 6 99 0.8× 36 0.5× 55 0.8× 28 0.5× 38 1.1× 11 141
Neil Sanghani United States 2 88 0.7× 48 0.7× 41 0.6× 19 0.3× 38 1.1× 4 140
Е. А. Chernyavskaya Russia 2 146 1.1× 78 1.1× 56 0.8× 30 0.5× 64 1.8× 8 215
Sohan Dua United States 3 224 1.7× 75 1.1× 101 1.5× 60 1.1× 100 2.8× 5 284
R Bhayadia Germany 7 20 0.2× 79 1.2× 11 0.2× 11 0.2× 8 0.2× 12 266
A. S. Gordon United States 8 80 0.6× 10 0.1× 11 0.2× 14 0.2× 38 1.1× 22 179
Valentina Vaja Italy 4 267 2.0× 12 0.2× 11 0.2× 7 0.1× 202 5.6× 5 310
C. Silliman United States 5 63 0.5× 6 0.1× 5 0.1× 253 4.4× 21 0.6× 9 393
Jing Xia China 8 39 0.3× 99 1.5× 94 1.4× 12 0.3× 20 302
Emmanuelle Charrin France 9 87 0.7× 6 0.1× 63 0.9× 2 0.0× 104 2.9× 14 218

Countries citing papers authored by Yoshimi Matsuda

Since Specialization
Citations

This map shows the geographic impact of Yoshimi Matsuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshimi Matsuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshimi Matsuda more than expected).

Fields of papers citing papers by Yoshimi Matsuda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshimi Matsuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshimi Matsuda. The network helps show where Yoshimi Matsuda may publish in the future.

Co-authorship network of co-authors of Yoshimi Matsuda

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshimi Matsuda. A scholar is included among the top collaborators of Yoshimi Matsuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshimi Matsuda. Yoshimi Matsuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Yamamoto, Hiroyasu, Kiyoshi Nobori, Yoshimi Matsuda, et al.. (2021). Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. American Journal of Nephrology. 52(10-11). 884–893. 27 indexed citations
2.
Akizawa, Tadao, Kiyoshi Nobori, Yoshimi Matsuda, et al.. (2021). Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single‐arm, open‐label, phase 3 study. Therapeutic Apheresis and Dialysis. 26(2). 368–377. 5 indexed citations
3.
Yamamoto, Hiroyasu, Kiyoshi Nobori, Yoshimi Matsuda, et al.. (2021). Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial. American Journal of Nephrology. 52(10-11). 871–883. 31 indexed citations
4.
Akizawa, Tadao, Takashi Yamada, Kiyoshi Nobori, et al.. (2021). Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis. Kidney International Reports. 6(10). 2604–2616. 35 indexed citations
5.
Akizawa, Tadao, Kiyoshi Nobori, Yoshimi Matsuda, et al.. (2021). Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single‐arm, phase 3 study. Therapeutic Apheresis and Dialysis. 25(6). 917–925. 8 indexed citations
6.
Akizawa, Tadao, Kiyoshi Nobori, Yoshimi Matsuda, et al.. (2021). MO542MOLIDUSTAT FOR ANAEMIA IN JAPANESE PATIENTS UNDERGOING PERITONEAL DIALYSIS: A SINGLE ARM, OPEN-LABEL, PHASE 3 STUDY. Nephrology Dialysis Transplantation. 36(Supplement_1). 1 indexed citations
7.
Yamamoto, Hiroyasu, et al.. (2020). P1868TO INVESTIGATE THE EFFICACY AND SAFETY OF MOLIDUSTAT IN NON-DIALYSIS PATIENTS WITH RENAL ANEMIA WHO ARE TREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS: MIYABI ND-M. Nephrology Dialysis Transplantation. 35(Supplement_3). 1 indexed citations
8.
9.
Akizawa, Tadao, Takashi Yamada, Kiyoshi Nobori, et al.. (2020). Results from a Phase 3 Study Comparing the Efficacy and Safety of Molidustat vs. Darbepoetin Alfa in Patients Receiving Hemodialysis and Treated with Erythropoiesis-Stimulating Agents (ESAs). Journal of the American Society of Nephrology. 31(10S). B4–B4. 2 indexed citations
10.
11.
12.
Saji, Tsutomu, Masafumi Myoishi, Koichiro Sugimura, et al.. (2016). Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension　– Insights From the IBUKI and AIR Studies –. Circulation Journal. 80(4). 835–842. 21 indexed citations
13.
Shimamoto, Kazuaki, et al.. (2015). Long-term safety and efficacy of high-dose controlled-release nifedipine (80 mg per day) in Japanese patients with essential hypertension. Hypertension Research. 38(10). 695–700. 8 indexed citations
14.
Wong, Tien Yin, Tatsuro Ishibashi, Kyoko Ohno‐Matsui, et al.. (2014). Efficacy and Safety of Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Pathological Myopia: 48-week Results of MYRROR Study. Investigative Ophthalmology & Visual Science. 55(13). 4960–4960. 1 indexed citations
15.
Matsuda, Yoshimi, et al.. (2014). Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. Clinical Nephrology. 82 (2014)(9). 181–190. 15 indexed citations
16.
Matsuda, Yoshimi, et al.. (2003). REDUCTION OF BACTERIAL CONTAMINATION USING A BLOOD COLLECTION SYSTEM WITH INTEGRATED PRE-DONATION DIVERSION POUCH. Journal of the Japan Society of Blood Transfusion. 49(6). 761–766. 1 indexed citations
17.
Matsuda, Yoshimi, et al.. (2003). Corrosion Resistance and Antimicrobial Activity of Copper-Containing Silica Films Prepared by Chemical Solution Deposition. Journal of the Ceramic Society of Japan. 111(1297). 698–701. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zeeshan Khawaja Breakdown of academic impact, for papers by Neil Sanghani Breakdown of academic impact, for papers by Е. А. Chernyavskaya Breakdown of academic impact, for papers by Sohan Dua Breakdown of academic impact, for papers by R Bhayadia Breakdown of academic impact, for papers by A. S. Gordon Breakdown of academic impact, for papers by Valentina Vaja Breakdown of academic impact, for papers by C. Silliman Breakdown of academic impact, for papers by Jing Xia Breakdown of academic impact, for papers by Emmanuelle Charrin
Rankless by CCL
2026